Tirzepatide
SURMOUNT-2
Eli Lilly · Phase 3 · Completed · Enrollment 938
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 10 milligrams (mg) Tirzepatide | n/r | n/r | n/r | n/r |
| 15 mg Tirzepatide | 86.41% | 69.58% | 51.78% | 33.98% |
| Placebo | 30.55% | 8.68% | 2.57% | 0.96% |
| 10 mg Tirzepatide | 81.55% | 63.43% | 41.42% | 22.98% |
Not shown
- 10 milligrams (mg) Tirzepatide: endpoint not reported